Advertisement
The study was completed by Rubina Heptulla, MD, from the Department ofPediatrics, Division of Endocrinology and Metabolism at the Baylor College ofMedicine and Texas Children's Hospital in Houston, Texas. "These data furtherdemonstrate that the 1,5-AG test is an effective measure of postprandialglucose concentrations and is particularly important in evaluating therapieswhich have shown efficacy in controlling postprandial hyperglycemia such asexenatide, pramlintide, and sitagliptin," said Dr. Heptulla. "We were alsoable to demonstrate that the normal range of 1,5-AG in children was similar tonormal adults reported in previous studies."
Advertisement
The results of this study are consistent with previous studies reported inadults. In a recent study published in the American Diabetes AssociationDiabetes Care journal (Dungan et al. Diabetes Care 2006; 29 (6): 1214-1219),it was shown that the GlycoMark 1,5-AG test reflected after-meal glucoselevels more robustly than the A1C test. The study also showed that GlycoMarkwas able to reveal dramatically different after-meal glucose levels inpatients with similar A1C levels.
Moreover, studies recently presented at the 67th Annual 2007 ScientificSessions of the American Diabetes Association and other meetings show thatGlycoMark is particularly valuable in detecting underlying treatment effectsof agents such as exenatide (Byetta) and pramlintide (Symlin) which were notrevealed by the gold standard hemoglobin A1C test. These findings haveimportant implications for patient care and pharmaceutical research as thereduction of after-meal glucose rises is a key objective of diabetes drugtherapy.
About GlycoMark
GlycoMark is an FDA approved test for monitoring intermediate glycemiccontrol by measuring the levels of a monosaccharide 1,5-anhydroglucitol(1,5-AG) in blood. Multiple published studies in peer-reviewed journals haveshown that the 1,5-AG test is a specific index of postprandial hyperglycemia(elevated after-meal glucose levels) and short-term glycemiccontrol -- providing a useful complement to A1C testing. GlycoMark is beingused in clinical practices nationwide and is available at major referencelaboratories including Quest Diagnostics, LabCorp, Esoterix, Mayo MedicalLaboratories, ARUP Laboratories, and Specialty Laboratories. The test is alsoavailable at most major contract research organizations for pharmaceuticalresearch studies.
GlycoMark is being commercialized by a partnership between Toyota TsushoAmerica (New York, NY), Nippon Kayaku (Tokyo, Japan) and the BioMarker Group(Kannapolis, NC). GlycoMark activities are centered in the North CarolinaResearch Campus in Kannapolis, North Carolina, a 350-acre life sciences hubstarted by billionaire David H. Murdock.
More information about GlycoMark may be found at www.glycomark.com.
SOURCE GlycoMark
